Organic Active Ingredients TRIZ Cases

Flow focusing nozzle shields macromer from crosslinker to form monodisperse microgel droplets, eliminating UV cytotoxicity.

Segmenting KRAS G12D and EGFR inhibition overcomes resistance mechanisms that limit monotherapy efficacy in colorectal cancer.

CX3CR1 antagonists block chemokine-receptor interactions to inhibit skeletal metastasis in primary breast or prostate cancers.

EDTA and oleic acid in clevidipine emulsions inhibit microbial growth for 24 hours, reducing contamination risks and drug wastage.

Segmented polymer backbones with triazole moieties resolve manufacturing precision issues to deliver controlled prostaglandin release.

A multilayer flexible film uses a co-polyester sealing layer to package transdermal patches.

A quinolinone compound inhibits prolyl hydroxylase domain enzymes to stabilize hypoxia-inducible factor alpha subunits.

Formula I retinoid derivatives overcome tumor cell resistance and epigenetic silencing of RAR-beta receptors.

Amine-functionalized mesoporous silica nanomaterials overcome antibiotic resistance by releasing copper ions and rafoxanide through pH-triggered swelling.

Nanoparticle formulation retains VEGF receptor inhibitors in posterior eye tissue for over 30 hours after systemic administration.

Novel benzamide derivatives act as positive allosteric modulators of the follicle stimulating hormone receptor.

Acetylated tricin derivatives combined with IL-12 gene therapy achieve 80% remission by synergistically activating dendritic cells and cytotoxic T cells.

Surfactant mediates between suspended formoterol and HFA 134a to prevent Ostwald ripening, ensuring chemical and physical stability.

Polysaccharide butyryl esters replace volatile free acids, increasing intestinal butyrate to reduce Salmonella colonization without antimicrobial resistance.

Single selenoether compounds resolve the contradiction between treatment simplicity and efficacy by reducing hepatic glucose output without combination therapy.

Detect SLC34A2 expression levels in muscle tissue using antibody-based assays to monitor facioscapulohumeral muscular dystrophy progression.

Formula I compounds stabilize the TYK2 pseudokinase auto-inhibitory conformation, reducing inflammation in autoimmune diseases.

Mature miR-197 nucleic acid molecules inhibit keratinocyte proliferation and inflammation in psoriatic skin lesions.

Formula I compounds bind Bcl-2 family proteins to inhibit anti-apoptotic activity.

L-arginine disrupts biofilm extracellular matrix stability, enabling antimicrobials like CPC to penetrate and kill pathogenic bacteria.

Formula I glycomimetics block E-selectin ligand interactions, preventing leukocyte recruitment and tissue damage in inflammatory diseases.

LeptiCore composition reduces body fat and metabolic biomarkers by combining plant extracts to overcome oxidative stress and leptin resistance.

Aqueous melatonin oral solutions use propylene glycol and sorbitol to enhance solubility.

Specific compounds modulate glycogen synthase and protein phosphatase-1 to reduce polyglucosan body content in tissues.

Specific inulin and partially hydrolyzed arabinoxylan ratios attenuate pro-inflammatory cytokine elevation to control systemic inflammation.

Dithiophosphate anchor groups stabilize gold nanoparticles against agglomeration while preserving surface reactivity for modular biomolecule attachment.

Self-assembling ternary conjugates combine passive EPR accumulation with active E-selectin binding to improve solubility and tumor specificity.

Irreversible azole inhibitors suppress regulatory T cells while enhancing effector T cells to combat tumor growth.

Specific substituent groups on the isoquinolinone core enhance V3 receptor selectivity, addressing insufficient efficacy of existing non-peptide ligands.

Segments dosing into immediate and extended-release phases to maintain blood glucose control while simplifying the regimen to once-daily administration.

DeepEntropy algorithm analyzes physiological signal complexity to overcome poor prognostic discrimination in standard clinical risk scores.

Conjugating cyclic cell-penetrating peptides to antisense compounds improves intracellular delivery efficiency while reducing carrier system complexity.

Anti-sclerostin antibodies increase bone formation and reduce resorption in osteogenesis imperfecta patients.

Enantiopure deuterium-enriched bupropion isolates active molecular forms to increase therapeutic potency.

Targeting filamin-A with siRNA or ribozymes alleviates PSP symptoms by reducing 4-repeat tau protein aggregation.

An mRNA multi-epitope vaccine design segments immunogenic proteins to target conserved T-cell and B-cell regions across viral variants.

Flexible six-month dosing intervals for extended-release paliperidone reduce relapse risk and weight gain while maintaining therapeutic plasma concentrations.

Novel compounds selectively inhibit Fms, Kit, Flt3, TrkA, TrkB, and TrkC kinases to treat rheumatoid arthritis and cancer with reduced side effects.

Enteric-release beads disperse opioid agonists within a polymer matrix to enable controlled intestinal absorption.

Segmentation and extraction remove saturated and polyunsaturated fatty acid interference to achieve high purity LC-MUFAs for medicaments.

Optimizing pH between 6.1 and 7.9 prevents active ingredient degradation, ensuring storage stability for interstitial cystitis treatment.

Formula I compounds modulate IL-17A activity to treat inflammatory disorders lacking effective therapies.

Self-microemulsion system dissolves abiraterone acetate to increase oral bioavailability, reducing food effect on absorption.

PEGylated TRPV1 prodrugs increase hydrophilicity to enable sterile aqueous formulations, reducing pungency and desensitization.

A low-temperature masterbatch process distributes drugs in polymer matrices.

N4-hydroxycytidine derivatives resolve bioavailability constraints through prodrug intermediaries for broad-spectrum antiviral therapy.

A pyrazolopyridine derivative activates lecithin cholesterol acyltransferase to promote macrophage cholesterol efflux.

Administering controlled-release vitamin D repletion and hormone replacement therapies to maintain stable blood concentrations of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D.

A combined preparation of hyaluronic acid, mucopolysaccharides, collagen, and whey protein isolate promotes muscular regeneration.

Measuring TRM cell molecular parameters identifies patients likely to benefit from targeted immunotherapy.

PCS6422 inhibits dihydropyrimidine dehydrogenase to protect 5-FU, reducing toxicity risks from variable metabolic rates.

Imiquimod cocrystals boost interferon production while reducing cytokine storm risks and improving bioavailability.

A calcium sulfate composite releases gentamicin to reduce microbial growth in bone defects.

Modified RNA vaccines encode proline-substituted antigens to generate high neutralization titers against emerging XBB variants.

Stable RPL-554 polymorph I crystallization eliminates unpredictable bioavailability shifts from phase transitions, ensuring consistent dosage strength.

Replacing lactose with non-hygroscopic mannitol resolves the contradiction between solubility and moisture stability in tadalafil orally disintegrating tablets.

A method using calcium ionophore to mimic physical exertion on cultured muscle cells for evaluating substance efficacy.

Corticosteroid premedication combined with step-up etentamig dosing lowers cytokine release syndrome incidence while maintaining therapeutic efficacy.

Benzamide compounds inhibit the P2X7 receptor to reduce neuroinflammation, addressing inadequate therapeutic outcomes in existing treatments.

Saponarin composition restores normal sleep patterns by increasing neuropeptide Y and GABA A α1 receptor mRNA expression to alleviate caffeine-induced insomnia.

Indazole-based PERK inhibitors reduce eIF2α phosphorylation, mitigating cytotoxicity while minimizing toxicity and enhancing brain bioavailability.

Combining type II anti-CD20 antibodies with prednisolone or doxorubicin overcomes treatment tolerance in recurrent CD20-positive cancers.

Extracted N-terminal fragments eliminate DPP-IV degradation and off-target VPAC activation, extending half-life while suppressing appetite.

Optimized cross-linking ratios resolve brittleness in thick skin, enabling sustained drug release for acute gout treatment.

Hyperbranched polylysine nanoparticles bind nucleic acids via electrostatic forces to form stable complexes for cellular uptake.

Ferrocene derivative compounds inhibit leukotriene synthesis via iron chelation.

RNA aptamers bind coagulation proteins to inhibit clot formation.

A hypometabolism-inducing agent containing T1AM inhibits Akt1-S6K synthesis pathways to induce muscular atrophy.

Lyophilized chitosan compressed into a porous matrix sustains mucoadhesion at physiological pH without harsh crosslinkers.

Local injection of stabilized miR-29 mimics reduces collagen overproduction in fibrotic tissues, avoiding systemic side effects.

Nanoencapsulated vitamin D analogs resolve toxicity trade-offs by enhancing solubility and stability via supercritical fluid processing.

Combining androgen deprivation therapy with radionuclide-labeled androgens eliminates castration-resistant prostate cancer initiating cells.

BRAF inhibitors reduce lipofuscin accumulation and reactive oxygen species to reverse permanent cell division halts.

Compounds occupy the hydrophobic groove within the Bcl-2/BAD complex to selectively trigger cell death without affecting normal tissue.

Oxycodone-processing enzyme converts drug into inactive form upon abuse.

Combines ellagitannins and proanthocyanidins to sustain KLF2 induction.

Bio-based N-acetyl-L-methionine uses microbial fermentation to produce high-yield amino acids.

Multiplexed molecular penetration enhancers improve corticosteroid skin permeability while reducing irritation from single-agent barriers.

Liquid polymerizable biodegradable macromonomers form in situ drug-eluting coatings on medical devices.

Segmented spherical nucleic acids with modified backbones achieve specific IL-17R mRNA knockdown in keratinocytes.

Inhaled phenylethylpyridine derivatives target airway receptors to suppress inflammation and relax smooth muscle while reducing systemic side effects.

Combining azabicyclo HSP90 inhibitors with other antitumor agents reduces side effects while enhancing antitumor efficacy.

Polyglycerol esters release 3-hydroxybutyric acid to reduce toxicity and nausea.

Tetracyclic heterocycle compounds inhibit HIV integrase activity, resolving efficacy and specificity limitations in current antiviral treatments.

Combining HER2 agents with IL6R inhibitors disrupts the inflammatory loop, preventing resistance in non-amplified tumors.

Lemborexant antagonizes orexin receptors to reduce sleep onset latency, addressing safety limitations of benzodiazepines.

A formula I compound inhibits Syk kinase activity to treat hematologic malignancies.

A hydrocortisone formulation with a delayed release polymer layer replicates natural cortisol rhythms, avoiding HPA axis suppression.

A pemetrexed pharmaceutical composition utilizes a low-concentration non-aqueous solvent to maintain chemical stability during storage.

A crystallization process using ethyl ether and ethanol yields thermodynamically stable needle-shaped Enclomiphene citrate.

Developing multiple crystalline and amorphous salt forms balances thermal stability with improved solubility to overcome manufacturing complexity.

Identify c-MYC 5' UTR variants and eIF4A activity to predict PI3K-mTORC1 inhibitor efficacy despite lack of druggable pockets.

Ketone carbonyl-introduced hydrophobic antitumor drugs form pH-responsive nano preparations via dehydration condensation with hydrazide-terminated polyethylene glycol.